Yarlas, Aaron http://orcid.org/0000-0003-4600-259X
Lovley, Andrew
Brown, Duncan
Kosinski, Mark
Vera-Llonch, Montserrat
Clinical trials referenced in this document:
Documents that mention this clinical trial
Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study
https://doi.org/10.1007/s00415-021-10635-1
Amyloid heart disease: genetics translated into disease-modifying therapy
https://doi.org/10.1136/heartjnl-2016-309914
Funding for this research was provided by:
Ionis Pharmaceuticals
Article History
Received: 28 April 2021
Revised: 27 May 2021
Accepted: 28 May 2021
First Online: 14 June 2021
Declarations
:
: AY, AL, and MK are employees of QualityMetric, which received payment from Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, to conduct these analyses and develop this manuscript. DB and MVL are employees of and own stock in Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals Inc.
: The trial protocol was approved by institutional review boards or local ethics committees. The trial was conducted in accordance with Good Clinical Practice guidelines of the International Conference on Harmonization and the principles of the Declaration of Helsinki.
: Written informed consent was obtained from all participants included in the study.